NCT06006013

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-01-15Est. Completion: 2027-12-16

Enrollment target: 21 participants

Locations

Emory University Hospital Midtown, Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Contact

Shahid S. Ahmed, MBBSshahid.sattar.ahmed@emory.edu 404-778-1900

Other microbiome trials you might be interested in

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)Phase 1Recruiting

Oesophageal Squamous Cell Carcinoma

The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ES…

Brno, CzechiaEst. completion Jun 12, 2027

View Trial →

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerPhase 2Recruiting

Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical CarcinomaStage III Adrenal Cortical Carcinoma AJCC v8Stage IV Adrenal Cortical Carcinoma AJCC v8Unresectable Adrenal Cortical Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.